Navigation Links
NightHawk Radiology exclusive radiology provider for high-risk plaque research initiative
Date:1/30/2008

COEUR DALENE, Idaho, January 30, 2008 Preventative heart healthcare gains strong momentum today as NightHawk Radiology Holdings, Inc. (Nasdaq: NHWK), announced its involvement as the exclusive radiology provider for the High-Risk Plaque Initiative (HRP Initiative). The HRP Initiative is a joint research effort to advance the understanding and management of high-risk plaque, which is believed to be the primary underlying cause of heart attacks and strokes.

As part of the research effort, NightHawks U.S. Board Certified radiologists will interpret Chest CT scans for approximately 6,000 study participants. Additionally, NightHawk Radiology Services expects its affiliated radiologists will read approximately 1,000 Cardiac CTA scans performed on a subset of participants believed to be at higher risk for a cardiac event. Cardiac CTA is a heart-imaging test that is rapidly gaining acceptance for its ability to non-invasively determine whether fatty or calcium deposits (i.e., plaque) have built up in the coronary arteries. The purpose of the interpretation of the CT Chest scans by NightHawks affiliated radiologists is to identify clinically significant cardiac and non-cardiac findings where the participant might benefit from its detection and follow-up.

Since there are currently no non-invasive methods of screening, diagnosis, or treatment for high-risk plaque, the HRP Initiatives goal is to provide a roadmap for the development of screening, diagnostic, and therapeutic interventions for high-risk plaque, and promote proper use to patients, providers and payors.

NightHawk was chosen because it was the single teleradiology provider with the strategic experience managing the complex technical aspects and reporting requirements of CCTA reconstructions, said Cherrill Farnsworth, President and Chief Executive Officer of HealthHelp, a radiology benefit management company that is coordinating the teleradiology aspect of the HRP Initiative. NightHawks resources, flexibility, and expertise place them at the forefront of CCTA and the 3D reconstruction. They are the only global provider with a viable solution that is available today.

NightHawk Radiology Services has deployed an independent imaging network solution explicitly for the HRP Initiative and it expects to begin evaluating reads in the first quarter of 2008.

We are very excited to be a part of this initiative, which involves high-profile medical institutions, leading pharmaceutical and medical technology companies, and scientists in the fields of cardiology, pathology, and imaging, said Dr. Paul Berger, Chairman and Chief Executive Officer of NightHawk Radiology Services. Participating in this initiative builds on the opportunities that lie ahead for our new service offerings such as CCTA, which we believe will continue to gain acceptance as the standard non-invasive diagnostic tool.


'/>"/>

Contact: Robert Minicucci
robert@warnerpr.com
603-488-5856
Warner Communications
Source:Eurekalert

Related medicine news :

1. NightHawk Radiology Holdings, Inc. Announces Date for Third Quarter Earnings Conference Call
2. NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results
3. NightHawk Radiology Holdings, Inc. to Speak at Annual Piper Jaffray Healthcare Conference on November 28, 2007
4. NightHawk Radiology: One Source, One Solution
5. NightHawk Radiology Holdings, Inc. to Speak at Annual JPMorgan Healthcare Conference on January 10, 2008
6. NightHawk Radiology Holdings, Inc. Announces Preliminary 2007 Results
7. NightHawk Radiology Holdings, Inc. Announces Date for Fourth Quarter and Full-Year 2007 Earnings Conference Call
8. AIUM CEO named among most influential in radiology
9. Abaxis Announces New Waived Kidney Check Panel Exclusively for Imaging and Radiology Centers
10. Franklin & Seidelmann Enters Full-Service Teleradiology Market with Acquisition of Apex Radiology
11. Radiology Ltd. Chooses AMICAS as End-to-End Solutions Provider
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: